AKT1 and cancer: As dysregulation of PI3K/AKT signaling is featured in tumorigenesis and proliferation of cancer cell proliferation, drugs targeting PI3K/AKT signalling, its downstream, or its upstream components have been attractive therapeutic avenues [58].